Artiva shares jump 12.81% intraday on positive AlloNK safety data and FDA Fast Track designation for refractory RA.

Artiva Biotherapeutics surged 12.81% intraday following the release of positive initial safety and translational data for its AlloNK therapy in autoimmune diseases. The company reported that 32 patients treated with AlloNK plus anti-CD20 monoclonal antibodies demonstrated consistent B-cell depletion by Day 13, with no severe adverse events like cytokine release syndrome or neurotoxicity. The FDA’s Fast Track Designation for AlloNK in refractory rheumatoid arthritis further underscored its potential as the first therapy in the deep B-cell depletion category to receive such regulatory prioritization. These developments, coupled with the feasibility of outpatient administration and plans for pivotal trial discussions in 2026, reinforced investor confidence in AlloNK’s clinical and commercial prospects, driving the sharp intraday rally.